Cargando…
Deep and lasting response and acquired resistance to BRAFV600E targeting in a low-grade ovarian cancer patient
The treatment of BRAFV600E mutant melanoma has been revolutionized by BRAF inhibitors. Furthermore, the BRAF/MEK combination has shown further improvement in clinical outcomes in advanced and in adjuvant melanoma patients. In low-grade ovarian tumors, BRAF inhibitor use has been also proposed. Here...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054366/ https://www.ncbi.nlm.nih.gov/pubmed/36967525 http://dx.doi.org/10.1080/15384047.2023.2193116 |